Feedback Share Discussion Threads

[bobd29] 22/1/2020 00:33

Hopefully more than just symbolic Duc but not sure of any real benefit. Always good to see communication however and I expect more substantial income news and contract wins this year. Current share price needs to be seen as very undervalued.

[ducatiman] 21/1/2020 19:43

Any views on today’s RNS?

[dplewis1] 21/1/2020 10:40

Their new office may as well be in St Thomas's

[ducatiman] 21/1/2020 10:24

Lawyers are leeches

[lr2] 21/1/2020 09:58

NHS blunders claiming 11,000 lives every year amid 'blame game' culture

[ged5] 21/1/2020 09:26

Notes from piece on TV:-

NHS claims
10000 new claims for negligence each year
83 bn outstanding claims
2.3 bn last year
Baby died because of a failure in care!
Hospital admitted liability years later
70% of cases resolved out of court
A system that doesn’t really seem to work for any of the people in it.
Mainly for babies injured
If more transparency at the start of the process cases wouldn’t go to court.

[lr2] 20/1/2020 17:22

TB sold out. I even predicted the last 3 digits of his final trade. And I was right. How do I know that? My prediction post and my celebratory 'he's gone' post were deleted sometime later. I'm guessing TB had them removed as he was the only person on this planet inconvenienced by them.

[ged5] 20/1/2020 16:14

It's not on the Market Screen list but neither is Barnard Nominees although BN is on the Feedback website.

[ged5] 20/1/2020 16:02

I've just updated the Major Shareholders section in the header. I thought TB had sold all his.

[ged5] 20/1/2020 15:43

That's welcome news Ashtree.

I hadn't realised University of Warwick had an agreement to use TexRAD.

Just looking at the website (it really does need updating/revamping) and noticed the Interims were on 24th January last year.

It's gone very quiet since lunch. A couple of large sells this morning. Now I wonder who that could be?

[lr2] 20/1/2020 14:22

This is a first study, using known regions of infarction, to identify and
predict from the initial CT imaging with image analysis classifiers the
area of potential future infarction. The TexRad™ software has been
demonstrated to identify the potential infarction with greater accuracy
than a reporting radiologist.

Next steps could include textural analysis of initial CT heads without
visible infarcts, by placing ROI in key areas affected by strokes and
correlating this with clinical symptoms to predict the likely location

[ducatiman] 20/1/2020 12:48

Yes, good to hear ash!!

[davydoo] 20/1/2020 12:44

Some big sales going through, but the price is holding up. That's encouraging

Would be great to leave the psychological 1p barrier behind us

[ashtree2] 20/1/2020 10:18

Ged...many thanks..very well and am bouncing back after the various procedures last year.I am still waiting for the results of the SVS securities chaos which has meant I have not been able to do anything significant on the share front.Leonard Curtis will hopefully resolve all this in the next couple of months.cheers.

[ged5] 20/1/2020 09:21

Thanks LR2. Yet another positive piece of news. FDBK look like they are moving in the right direction. It's another pointer that the trials are going well after the very promising remarks in the interview. 237 views last time I looked. Nobody interested here!

Hi Ashtree. Are you keeping well?

[ashtree2] 20/1/2020 07:14

IQ-AI has received notification that the Korean FDA (KFDA) has cleared StoneChecker Software for marketing in the Republic of Korea, a key market for high-tech medical imaging hardware and software. In addition, Imaging Biometrics (IB) has received GMP certification.

Trevor Brown, Chief Executive of IQ-AI commented, "We are delighted that StoneChecker Software has received KFDA approval for marketing in the Republic of Korea, our Korean distributor's marketing plans can now be fully implemented. It also gives me great pleasure to welcome back Dr Balaji Ganeshan to the team. Dr Ganeshan, an exceptionally innovative medical imaging entrepreneur and scientist, has invaluable expertise and ideas in a number of key technologies relevant to the Company. He will be working as a consultant for IB."

[lr2] 19/1/2020 21:05

When the user feedback from the trial run is overwhelmingly positive and all modifications have been made, then it's time to write the user manuals.



"Focusing initially on our innovative new product, BleepaTM, you will develop copy for brand communications, user guides, positioning statements, video & animation scripts, web copy, advertising campaigns, social, media and email marketing campaigns, internal and external news updates.

Working with the Marketing Director and associated teams, you will help plan and deliver a comprehensive marketing programme."
___________________________________

(Hint to project manager - when you've got the final agreed update list completed and are ready to move to the next (and hopefully final) version, do not forget to add a further test for scalability. Run those scalability tests against the completed updates list.)

[bobd29] 19/1/2020 12:19

Morning Duc and Ged, lot of work going on and a new income stream should indicate a rerate but I get the feeling FDBK is paying the price for previous unfulfilled promise. Actual income figures and forward projections or specific trading update are needed to get investor confidence. I think we could be turning a corner and maybe 2020 will be the year when FDBK realises it’s potential and becomes profitable, if so perhaps CoffeeCups will be proven right. See what next week brings.

[ged5] 19/1/2020 11:14

The video of the talk (text is above)from 1st October 2019. Tom Oakley is speaking from 13.15.

[ged5] 19/1/2020 10:44

I wasn't sure what a sandbox was.

A sandbox is a type of software testing environment that enables the isolated execution of software or programs for independent evaluation, monitoring or testing. In an implementation, a sandbox also may be known as a test server, development server or working directory.